Ibrutinib with R-CHOP Differentially Affects Genetic Subtypes of DLBCL

Skip Nav Destination

Article navigation

Research Watch| January 12 2022

Online Issn: 2159-8290

Print Issn: 2159-8274

2021

American Association for Cancer Research.

Cancer Discov (2022) 12 (1): OF7.

Abstract

The genetic classification of DLBCL identified subgroups that benefit from addition of ibrutinib and its underlying mechanism.

2021

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.